MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Open Access Journal of Cardiology
ISSN: 2578-4633

Coronary No-Reflow after Primary Percutaneous Coronary Intervention

Emara H*

Department of Cardiology, Norfolk and Norwich University hospital, UK

***Corresponding author:** Haytham Emara, Department of Cardiology, Norfolk and Norwich University hospital, UK, Email: Haythamemara147@hotmail.com

Mini Review
Volume 8 Issue 1
Received Date: July 29, 2024
Published Date: August 16, 2024
DOI: 10.23880/oajc-16000205

Abstract

Coronary no-reflow is a significant complication following primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction. This phenomenon involves inadequate myocardial perfusion despite successful vessel recanalization, attributed to factors such as microvascular injury, inflammation, thrombus embolization, and vasospasm. Effective management strategies include pharmacological agents, mechanical interventions, and optimized antithrombotic therapy. Prompt diagnosis and treatment are essential to enhance patient outcomes and reduce adverse effects associated with this condition.

Keywords: No-Reflow; Perfusion; Infarction; Thrombectomy; Angioplasty

Abbreviation

PCI: Percutaneous Coronary Intervention.

Introduction

It is increasingly recognized that tissue perfusion, rather than merely achieving an open artery, is crucial for saving the heart. Many patients remain at risk of significant infarcts even after thrombolytic drugs or PTCA-assisted recanalization successfully restores partial and prolonged myocardial reperfusion. The primary goals of reperfusion therapy are to restore blood flow in the epicardial coronary artery and achieve sustained and complete reperfusion of the infarcted myocardium [1].

Body of Paper

There is concern that the myocardium may suffer additional damage during the reperfusion phase. When blood flow is restored to an area that was previously ischemic, significant physiological and anatomical changes occur, such as tissue edema, neutrophil infiltration, microvascular damage, and subsequent reduction in microcirculatory flow. Therefore, the optimal reperfusion regimen for patients with STEMI should include ancillary and adjunctive treatments that reduce microvascular damage and protect the myocardial infarct zone, which contains cells at various stages of ischemia, necrosis, and apoptosis, in addition to the primary methods of restoring flow in the epicardial infarct artery (pharmacological or catheter-based) [2].

A coronary blood flow of less than TIMI 3, without severe stenosis, dissection, or an angiographically detected thrombus distal to the area of the IRA where PCI was performed, is referred to as no-reflow [3].

In the no-reflow zone, tissue edema, endothelial disruption, neutrophil and microthrombi plugging capillaries, complement component activation, inflammation from free radical production, and contracture of nearby myocytes cause the capillary structure to become disorganized. Coronary reperfusion facilitates these changes, making part of the no-reflow phenomenon attributable to reperfusion damage [4].

Various factors contribute to the no-reflow phenomenon, depending on whether microemboli are introduced into small arteries or arterioles, or if capillaries are destroyed or obstructed. Factors such as the length of coronary occlusion, the amount of myocardium supplied by the occluded artery, the patency of the infarct-related artery, the quality of collateral circulation, and the presence of preinfarction angina influence capillary obstruction, just as they influence myocardial necrosis following AMI [5].

Lipid-rich plaques susceptible to rupture during PCI are likely to generate microemboli. The release of plaque constituents, such as cholesterol crystals, macrophages, and platelet-fibrin complexes, may induce arteriole spasm, potentially causing additional microvascular blockage, thrombosis, and slow coronary flow. Typically, this restriction is temporary [6].

Clinical Consequences of the No-Reflow Event

Since the no-reflow phenomenon occurs after the local myocytes have already died, it is highly unlikely that function will later restore. A wide no-reflow zone is associated with reduced left ventricular contractile performance, and the absence of reflow also indicates a higher likelihood of acute complications following AMI. Patients exhibiting no-reflow represent the highest-risk subset of those undergoing reperfusion, with increased risks of both death and persistent congestive heart failure. A sizable no-reflow area may impede the infarct's potential for healing and obstruct the distribution of therapeutic medications to that area. Transmural injury is common, and significant transmural injury may lead to early left ventricular dilatation and infarct expansion. The no-reflow phenomenon has been linked to cardiac rupture and ventricular arrhythmias, and it may adversely affect left ventricular remodeling following AMI. Follow-up studies have associated the no-reflow phenomenon with reduced ejection fraction, increased risk of cardiac death, and malignant arrhythmias, all of which have significant therapeutic implications [7].

Reperfusion therapy is no longer solely about opening the target artery; it also involves enhancing the patency of the microvasculature in the affected area [8].

Intense antiplatelet therapy with aspirin and clopidogrel, platelet glycoprotein-IIb/IIIa-receptor inhibitors, coronary vasodilators, and embolization prevention devices are examples of adjunctive therapies that reduce microemboli. Thrombolytic medications do not appear to improve microvascular performance [8].

Catheter-based devices include distal protection devices designed to capture embolic debris, and others that directly aspirate thrombus and plaque contents at the occlusion site. These devices fall into two categories: filter wire devices, which can be collapsed and withdrawn from the artery with the trapped debris, and balloon-occlusion devices, which are deployed at the distal site of a vulnerable plaque during PCI to temporarily occlude the vessel and then remove the debris with an aspiration catheter. Both types of devices can effectively remove embolic debris in most AMI patients undergoing emergency PCI. However, distal embolic protection does not always result in smaller infarcts, better event-free survival, or improved microvascular flow or reperfusion success [9].

The AngioJet rheolytic thrombectomy system (Possis Medical Inc., Minneapolis, MN) uses high-velocity, high-pressure saline jets through orifices at the distal tip of a catheter to create a localized low-pressure zone, removing thrombus using the Venturi-Bernoulli effect. This process entrains and dissociates bulky thrombus, creating a vacuum effect. AMI patients may experience reduced thrombus load after rheolytic thrombectomy with the AngioJet catheter. Long-term follow-up in a small study showed better outcomes for AMI patients treated with rheolytic thrombectomy compared to traditional primary angioplasty [10].

Research indicates that short-term, multiple coronary occlusions occurring shortly after prolonged myocardial ischemia are associated with a smaller myocardial infarct size compared to abrupt reperfusion. This cardioprotective measure is known as postconditioning. The protective process involves nitric oxide synthesis, opening of mitochondrial potassium channels, prevention of mitochondrial permeability transition pore opening, and activation of extracellular signal-regulated kinase. A similar strategy might be used in the cardiac catheterization laboratory after primary angioplasty in AMI patients to preserve the reperfused myocardium [11].

If myocytes and the microvasculature can be shielded from ischemic injury, reperfusion injury, or both, postischemic microvascular flow would increase, and functional and clinical outcomes would improve. Beyond its ability to dilate blood vessels, adenosine provides additional benefits that make it a viable treatment option. Adenosine preserves endothelial integrity, reduces neutrophil counts in infarct zones, and may have cardioprotective effects similar to ischemic preconditioning. Intracerebral delivery of 24-48 micrograms of adenosine improves ventricular performance and microvascular health in the infarct zone in AMI patients, enhancing clinical outcomes following percutaneous coronary intervention [12].

When administered prior to reperfusion, the mitochondrial potassium-channel opener nibandil, which

has a nitrate component, has shown promising effects in AMI patients. This medication reduces calcium overload in myocytes, dilates coronary resistance arteries, decreases preload and afterload, and lessens neutrophil activation. Nicorandil may protect the heart from ischemic damage as the mitochondrial potassium channel is an end effector of the ischemic preconditioning pathway. Research has shown that patients who received intravenous nicorandil during reperfusion had improvements in microvascular perfusion, reduced infarct size, and better clinical outcomes [13].

Conclusion

Coronary no-reflow is a significant complication in primary PCI for acute myocardial infarction, resulting from factors like microvascular injury and thrombus embolization. Early recognition and intervention are crucial for improving patient outcomes. The AngioJet thrombectomy system, alongside pharmacological strategies, shows promise in enhancing revascularization and mitigating adverse effects.

References

1. VandeWerf F (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 24: 28-66.

2. Gibson CM (2003) Has My Patient Achieved Adequate Myocardial Reperfusion. Circulation 108: 504-507.

3. Annibali G, Scrocca I, Aranzulla TC, Meliga E, Maiellaro F, et al. (2022) No-Reflow Phenomenon: A Contemporary Review. Journal of Clinical Medicine 11(8): 2233.

4. Manciet LH, Poole DC, McDonagh PF, Copeland JP, Mathieu-Costello O (1994) Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. American Journal of Physiology-Heart and Circulatory Physiology 266(4): H1541–H1550.

5. Ito H (2006) No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nature Clinical Practice Cardiovascular Medicine 3(9): 499-506.

6. Reffelmann T, Kloner RA (2006) The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Research in Cardiology 2006; 101(5): 359-372.

7. Galasso G, Schiekofer S, D'Anna C (2013) No-Reflow Phenomenon. Angiology 65: 180-189.

8. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, et al. (2001) Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nature Medicine 7(4): 430-436.

9. Gersh BJ, Stone GW, White HD, Holmes DR (2005) Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. JAMA 293(8): 979-986.

10. Li GQ, Wang L, Zhang XC (2021) AngioJet Thrombectomy Versus Catheter-Directed Thrombolysis for Lower Extremity Deep Vein Thrombosis: A Meta-Analysis of Clinical Trials. Clinical and Applied Thrombosis/ Hemostasis 27.

11. Galiuto L (2004) Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification. Heart 90(2): 123-125.

12. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, et al. (2010) 5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology 55(21): 2383-2389.

13. Yu Y, Wu Y, Wu X, Wang J, Wang C (2022) Risk Factors for No-Reflow in Patients with ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Case-Control Study. Cardiology Research and Practice pp: 1-7.